Linking Biotech Value Creation And The Exit Strategy

Why you should begin your journey with the end in mind

Entrepreneurial scientists often believe that the science they’re working on is ‘it,’ that investors will clamor for ‘it,’ and regulators can’t wait to approve ‘it.’ That kind of fervor is a good thing; it drives progress and innovation. But somewhere along the biopharma’s entrepreneurial journey, business realities set in. Realities like capital, competition, regulations, business execution, and the ‘end game.’ Not all scientists—even those with entrepreneurial dreams of life-changing exits—are equipped to manage the complexities born not of the science, but of the business of science.

Dr. Francois Nader knows this, and he says it’s okay. He’s a business builder and exit strategist extraordinaire, but he was a scientist first. Dr. Nader sat down with The Business Of Biotech, (produced by BioProcess Online and supported by Cytiva), to discuss the business side of biopharma, and more specifically, why it's important for emerging biopharma leaders to launch with the end in mind, and what that means in the contexts of building company valuation and maximizing the exit.